Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
- PMID: 32944298
- PMCID: PMC7475604
- DOI: 10.21037/jtd.2020.04.45
Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2020.04.45). NP reports grants and personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, Gaurdant360, Genesort, Merk, Merck Sharp & Dohme, Novartis, NovellusDx, Pfizer, Roche, Takeda, other from LOXO. The other authors have no conflicts of interest to declare.
Comment on
-
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.J Thorac Dis. 2019 Dec;11(12):4982-4991. doi: 10.21037/jtd.2019.12.24. J Thorac Dis. 2019. PMID: 32030214 Free PMC article.
References
-
- Kian W, Roisman LC, Levitas D, et al. Non-small cell lung cancer PDL1 >50%—should we go single or combo? Precis Cancer Med 2020;3:7. 10.21037/pcm.2019.11.08 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Research Materials